Business
Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple poster presentations across its rare neurological disease platform at the American Academy of Neurology (AAN) 2020 Annual Meeting in Toronto (April 25-May 1).\n “We are pleased by the breadth of data selected for presentation at this year’s AAN conference, which underscores our efforts to find treatments for patients living with rare neurological conditions like Angelman syndrome, Fragile X syndrome and rare epilepsies,” said Amit Rakhit, M.D., MBA, President and Chief Medical Officer at Ovid. “We look forward to joining world-renowned neurologists and researchers attending AAN to present our findings and continue to push the envelope in the name of patients and their families, who inspire us every day.” AAN 2020 Annual Meeting Presentation Details Presentations on OV101 (gaboxadol) in Neurodevelopmental Disorders: Title: The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions Poster No.: 009 Poster Session 5: Research Methodology, Education, and History Date and Time: Monday, April 27, 8:00 – 9:00 a.m. ET Title: The pivotal Phase 3 NEPTUNE trial investigating gaboxadol in Angelman syndrome: Study design Poster No.: 015 Poster Session 13: Neuromuscular and Clinical Neurophysiology (EMG) Date and Time: Wednesday, April 29, 5:30 – 6:30 p.m. ET Title: Evidence of pharmacodynamic tolerance during repeated daily gaboxadol exposure in individuals with Angelman syndrome Poster No.: 011 Poster Session 13: Neuromuscular and Clinical Neurophysiology (EMG) Date and Time: Wednesday, April 29, 5:30 – 6:30 p.m. ET Title: Physiologically based pharmacokinetic modeling (PBPK) for gaboxadol exposure in children with Angelman syndrome Poster No.: 012 Poster Session 13: Neuromuscular and Clinical Neurophysiology (EMG) Date and Time: Wednesday, April 29, 5:30 – 6:30 p.m. ET Title: Caregiver insight on the core domains in Angelman syndrome Poster No.: 013 Poster Session 13: Neuromuscular and Clinical Neurophysiology (EMG) Date and Time: Wednesday, April 29, 5:30 – 6:30 p.m. ET Title: Quality of life in adolescent and adult individuals with ...